The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 777-782

  Deau, Bénédicte ^a   Nicolini, Franck E ^b   Guilhot, Joelle ^c   Huguet, Françoise ^d   Guerci, Agnès ^e   Legros, Laurence ^f   Pautas, Cécile ^g   Berthou, Christian ^h   Guyotat, Denis ⁱ   Cony Makhoul, Pascale ^j   Gardembas, Martine ^k   Michallet, Mauricette ^b   Hayette, Sandrine ^b   Cayuela, Jean Michel ^l   Weiss, Isabelle Radford ^a   Réa, Delphine ^l   Castaigne, Sylvie ^m   Mahon, François Xavier ⁿ   Guilhot, François ^c   Rousselot, Philippe ^m  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c INSERM   (France)

^d CHU PURPAN   (France)

^e CHU NANCY BRABOIS   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^j CH d'Annecy   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m HAUT LÉVÊQUE HOSPITAL   (France)

ⁿ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

more..

Author keywords

Chemotherapy; CML; Imatinib mesylate; Myeloid blast crisis; Ph+ AML

Indexed keywords

CYTARABINE; DAUNORUBICIN; IMATINIB;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER DYSFUNCTION; LUNG INFECTION; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOID BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA; NAUSEA; NEUTROPENIA; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEUTROPENIA; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955583107     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.004     Document Type: Article

References (20)

1. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061. IRIS Investigators, Erratum in: Leukemia 2010;24:1102.
2. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
3. Kantarjian H.M., Shan J., Smith T., Talpaz M., Kozuch P., Rios M.B., et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 2001, 92:2501-2507.
4. Sacchi S., Kantarjian H.M., O'Brien S., Cortes J., Rios M.B., Giles F.J., et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999, 86:2632-2641.
5. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042. Erratum in: N Engl J Med 2001;345:232.
6. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
7. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
8. Kantarjian H.M., Cortes J., O'Brien S., Giles F.J., Albitar M., Rios M.B., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99:3547-3553.
9. Cortes J., Rousselot P., Kim D.W., Ritchie E., Hamerschlak N., Coutre S., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213.
10. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
11. Cortes J., Kim D.W., Raffoux E., Martinelli G., Ritchie E., Roy L., et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176-2183.
12. Sureda A., Carrasco M., de Miguel M., Martínez J.A., Conde E., Sanz M.A., et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003, 88:1213-1220.
13. Fang G., Kim C.N., Perkins C.L., Ramadevi N., Winton E., Wittmann S., et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246-2253.
14. Kano Y., Akutsu M., Tsunoda S., Mano H., Sato Y., Honma Y., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999-2007.
15. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000, 96:3195-3199.
16. Topaly J., Zeller W.J., Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001, 15:342-347.
17. Palandri F., Castagnetti F., Testoni N., Luatti S., Marzocchi G., Bassi S., et al. GIMEMA Working Party on Chronic Myeloid Leukemia Chronic myeloid leukemia in blast crisis treated with imatinib 600mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008, 93:1792-1796.
18. Fruehauf S., Topaly J., Buss E.C., Fischer T., Ottmann O.G., Emmerich B., et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007, 109:1543-1549.
19. Quintás-Cardama A., Kantarjian H., Garcia-Manero G., O'Brien S., Faderl S., Ravandi F., et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 2007, 48:283-289.
20. Nicolas-Virelizier E, Jacquet-Lagreze M, Waz D, Réa D, Coiteux V, Leguay T et al. Combined chemotherapy (daunorubicine+cytarabine) and dasatinib as salvage therapy of chronic myeloid leukemia in myeloid blast crisis, a pilot study. ASH annual meeting abstracts, vol. 114; 2009. p. 219.